Does Depakote cause hair loss? Yes — hair loss is a recognised side effect of valproate medicines, including Depakote (valproate semisodium), sodium valproate (Epilim), and valproic acid. Listed in UK product information approved by the MHRA, this side effect is medically termed telogen effluvium — a diffuse shedding caused by premature disruption of the hair growth cycle. Used to treat epilepsy and bipolar disorder, valproate medicines are highly effective, and for most patients the benefits outweigh this risk. Understanding why hair loss occurs, how common it is, and what can be done about it helps patients make informed decisions alongside their healthcare team.

Does Valproate (Including Depakote) Cause Hair Loss?

Yes — hair loss is a recognised, MHRA-listed side effect of all valproate medicines, presenting as telogen effluvium (diffuse shedding). It is generally non-scarring and regrowth is typically possible, particularly if the dose is reduced or the medicine is changed.

Depakote is a brand name for valproate semisodium (also known as divalproex sodium), one of several valproate medicines available in the UK. Other valproate products include sodium valproate (brand name Epilim) and valproic acid. These medicines are used to treat epilepsy and bipolar disorder. Valproate is sometimes used off-label for migraine prevention, though this is not a licensed UK indication and is generally avoided — particularly in women of childbearing potential — under the MHRA's Valproate Pregnancy Prevention Programme (PPP). Valproate medicines work primarily by enhancing the activity of gamma-aminobutyric acid (GABA) in the brain, reducing abnormal electrical activity and helping to stabilise mood.

Yes — hair loss is a recognised side effect of valproate medicines. It is listed in the UK product information (Summary of Product Characteristics, SmPC) approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and available via the Electronic Medicines Compendium (emc). The medical term for this pattern of hair loss is telogen effluvium, a condition in which hair follicles are prematurely pushed into the resting (telogen) phase of the hair growth cycle, leading to diffuse shedding across the scalp.

Not everyone who takes a valproate medicine will experience hair loss. For many patients, the benefits of the medication — particularly in controlling seizures or stabilising mood — significantly outweigh this potential side effect. Hair loss associated with valproate is generally non-scarring, meaning the hair follicles themselves are not permanently damaged, and regrowth is typically possible, particularly if the dose is reduced or the medicine is changed. Understanding the nature and likelihood of this side effect can help patients make informed decisions in partnership with their healthcare team.

How Common Is Hair Loss With Valproate Medicines?

Alopecia affects an estimated 12–28% of patients taking valproate, with onset usually within the first three to six months. The BNF notes it is often transient and may resolve even with continued use.

The frequency of alopecia (hair loss) varies across valproate products and their UK SmPCs. Some SmPCs classify alopecia as very common (affecting 1 in 10 or more people), whilst others list it as common (affecting between 1 in 100 and 1 in 10 people). Patients and clinicians should refer to the SmPC for the specific product prescribed, available via the emc. Published clinical studies suggest that noticeable hair thinning or shedding may affect approximately 12% to 28% of patients during treatment, though robust UK-specific incidence data are limited.

The onset of hair loss typically occurs within the first three to six months of starting treatment, though it can develop at any point during therapy, including after dose increases. In many cases, shedding is most pronounced in the initial period and may stabilise or improve over time, even without changes to the medication. However, for some individuals, hair loss can persist throughout the duration of treatment. The BNF notes that alopecia associated with valproate is usually transient and may resolve even with continued use.

Several factors may influence the likelihood and severity of hair loss, including:

• Higher doses of valproate

• Longer duration of treatment

• Nutritional status, particularly zinc and selenium levels, which some studies suggest valproate may reduce — though evidence is mixed and this is not a standard SmPC claim

• Individual susceptibility to drug-induced hair changes

• Concurrent medications that may also affect hair growth

It is worth noting that hair loss can also result from the underlying conditions being treated — for example, the physiological stress of poorly controlled epilepsy or a mood episode — making it sometimes difficult to attribute shedding solely to the medication. A thorough clinical assessment is therefore important before drawing conclusions.

Why Valproate May Affect Hair Growth

Valproate is thought to prematurely shift hair follicles from the active growth (anagen) phase into the resting (telogen) phase, causing diffuse shedding. Additional proposed mechanisms include effects on zinc and selenium levels, HDAC inhibition, and thyroid function.

The precise mechanisms by which valproate causes hair loss are not fully established, but several biological pathways have been proposed.

Disruption of the hair growth cycle is the most widely accepted explanation. Hair normally cycles through three phases: anagen (active growth), catagen (transition), and telogen (resting/shedding). Valproate is thought to prematurely shift hair follicles from the anagen phase into the telogen phase, resulting in diffuse shedding consistent with telogen effluvium. This typically presents as generalised thinning rather than patchy bald spots.

Zinc and selenium status may also play a role. Some studies have reported reduced serum levels of zinc and selenium in patients taking valproate, and both minerals are important for healthy hair follicle function. Zinc is involved in protein synthesis and cell division within the follicle, whilst selenium contributes to antioxidant defence. However, the evidence for valproate-induced micronutrient depletion is mixed, and routine testing or supplementation is not part of standard UK clinical practice; any investigation or supplementation should be clinician-led.

Valproate is also a known inhibitor of histone deacetylase (HDAC), an enzyme involved in regulating gene expression. This epigenetic activity may theoretically interfere with signalling pathways governing hair follicle cycling, though this remains an area of ongoing research and is not yet a confirmed clinical mechanism.

Finally, valproate may affect thyroid function in a small number of patients, and thyroid dysfunction is a well-established cause of diffuse hair loss. Thyroid testing is not routinely required but is clinician-directed when symptoms or signs suggest possible dysfunction (such as fatigue, weight change, or cold intolerance). The Primary Care Dermatology Society (PCDS) and British Association of Dermatologists (BAD) provide guidance on the assessment of drug-induced telogen effluvium that may be helpful for clinicians managing affected patients.

Managing Hair Loss Whilst Taking Valproate

Management options include clinician-led nutritional assessment, gentle hair care practices, specialist-supervised dose review, and — in persistent cases — off-label topical minoxidil under clinician supervision. Any medication or supplement changes must be discussed with a prescribing doctor.

If you notice hair thinning or increased shedding whilst taking a valproate medicine, there are several approaches that may help manage this side effect without necessarily discontinuing treatment. Any changes to your medication or supplement regimen should be discussed with your prescribing doctor or specialist.

Nutritional assessment and supplementation may be considered in some cases. Some studies suggest that zinc or selenium supplementation can reduce hair loss in patients taking valproate, particularly where deficiency is confirmed. However, evidence remains limited and this is not part of standard UK guidance. Testing and supplementation should be clinician-led rather than self-initiated, as excessive intake of zinc or selenium can itself be harmful. If you are taking any supplements, inform your doctor, as high-dose biotin (vitamin B7) in particular can interfere with certain laboratory assays and affect test results.

Practical hair care adjustments can help minimise further damage to already fragile hair:

• Use gentle, sulphate-free shampoos and avoid harsh chemical treatments

• Reduce heat styling (blow-drying, straightening, curling)

• Avoid tight hairstyles that place tension on the scalp

• Handle wet hair gently, as it is more susceptible to breakage

Dose review is another option your specialist may consider. In some cases, reducing the dose of valproate — if clinically appropriate and safe — may lessen the severity of hair loss. This must always be done under specialist supervision, as abrupt changes to anticonvulsant or mood-stabilising therapy carry significant risks, including seizure recurrence or mood relapse.

A GP or dermatologist may also consider topical minoxidil in persistent cases. It is important to note that its use for drug-induced telogen effluvium is off-label and evidence in this specific context remains limited; it should only be used under clinician supervision. The NHS, PCDS, and BAD provide patient-facing information on hair loss management that may be a useful starting point.

It is also important to consider common alternative causes of diffuse hair loss — including iron deficiency, thyroid disease, and androgenetic alopecia — before attributing shedding solely to valproate.

When to Speak to Your GP or Specialist

Contact your GP or specialist promptly if hair loss is rapid, severe, patchy, or accompanied by symptoms such as fatigue or weight change, or if you are considering stopping valproate — never stop abruptly, as this risks seizures or mood relapse.

Whilst hair loss from valproate is generally not medically dangerous, it can significantly affect a person's quality of life, self-esteem, and willingness to continue with treatment. It is always appropriate to raise concerns about side effects with your prescribing doctor or specialist — doing so promptly allows for timely assessment and management.

You should contact your GP or specialist if:

• Hair loss is rapid, severe, or causing significant distress

• You notice patchy hair loss (which may suggest alopecia areata or another cause requiring separate assessment)

• You develop scalp pain, inflammation, or scarring, which may indicate a condition requiring urgent dermatological review

• Hair loss is accompanied by other symptoms such as fatigue, unexplained weight change, cold intolerance, acne, hirsutism, or menstrual irregularity (which may point to thyroid or hormonal dysfunction)

• You are considering stopping or reducing your medication — never stop valproate abruptly without medical advice, as this can trigger seizures or mood episodes

• Hair loss begins or worsens after a dose increase, which may warrant a medication review

Your doctor may arrange blood tests to investigate potential contributing factors. In primary care, the most appropriate initial investigations are typically:

• Full blood count (FBC) and serum ferritin (to exclude iron deficiency)

• Thyroid function tests (TFTs)

Assessment of serum zinc, selenium, or valproate drug levels is generally more appropriate in a specialist setting and should be guided by clinical context rather than requested routinely.

Open communication with your healthcare team is essential. The decision to continue, adjust, or change medication should always be made collaboratively, weighing the benefits of seizure or mood control against the impact of side effects on daily life. NICE CKS guidance on alopecia provides a useful framework for primary care assessment and referral.

Alternative Medications and MHRA Safety Considerations

Alternatives such as lamotrigine or levetiracetam may be considered by specialists where hair loss is severe, but no switch should be made without specialist input. Valproate is contraindicated in pregnancy under the MHRA Valproate Pregnancy Prevention Programme.

For patients in whom hair loss is severe, persistent, or significantly affecting wellbeing, a specialist may consider whether an alternative medication is appropriate. However, this decision is complex and highly individual.

It is important to note that valproate medicines are contraindicated in pregnancy due to well-documented risks of serious birth defects and developmental problems in children exposed in the womb. Under the MHRA's Valproate Pregnancy Prevention Programme (PPP), valproate must not be used in women or girls of childbearing potential unless they are enrolled in the PPP, have a signed risk acknowledgement form, and are using highly effective contraception. Prescribers, patients, and carers are encouraged to consult the MHRA's valproate safety hub for current PPP materials and requirements.

Alternative anticonvulsants or mood stabilisers that are less commonly associated with hair loss include lamotrigine, levetiracetam, and lithium (for bipolar disorder), though each carries its own side effect profile and suitability depends on the individual's diagnosis, seizure type, and medical history. In line with NICE Guideline NG217 (Epilepsies in children, young people and adults) and NICE guidance on bipolar disorder, lamotrigine is now preferred over valproate for many women of childbearing age. However, lamotrigine may worsen certain seizure types — including myoclonic seizures — and is not appropriate for all patients. Alternative antiseizure medicine (ASM) selection must always be guided by seizure type and specialist assessment.

No medication switch should be made without specialist input. Sodium valproate and valproate semisodium remain among the most effective treatments available for certain epilepsy syndromes and bipolar disorder, and for many patients — particularly those with treatment-resistant conditions — the risks of switching may outweigh the benefits of resolving a side effect.

The MHRA continues to monitor the safety profile of valproate medicines and updates prescribing guidance accordingly. Patients and carers are encouraged to report suspected side effects — including hair loss — through the MHRA Yellow Card scheme (available via the MHRA website or the Yellow Card app), which helps regulators identify emerging safety signals and improve patient care across the UK.

Frequently Asked Questions